{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:39:29Z","timestamp":1770500369227,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2002,1,1]]},"DOI":"10.1038\/sj.tpj.6500072","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:54:25Z","timestamp":1031252065000},"page":"43-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":571,"title":["UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity"],"prefix":"10.1038","volume":"2","author":[{"given":"L","family":"Iyer","sequence":"first","affiliation":[]},{"given":"S","family":"Das","sequence":"additional","affiliation":[]},{"given":"L","family":"Janisch","sequence":"additional","affiliation":[]},{"given":"M","family":"Wen","sequence":"additional","affiliation":[]},{"given":"J","family":"Ram\u00edrez","sequence":"additional","affiliation":[]},{"given":"T","family":"Karrison","sequence":"additional","affiliation":[]},{"given":"G F","family":"Fleming","sequence":"additional","affiliation":[]},{"given":"E E","family":"Vokes","sequence":"additional","affiliation":[]},{"given":"R L","family":"Schilsky","sequence":"additional","affiliation":[]},{"given":"M J","family":"Ratain","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2002,3,14]]},"reference":[{"key":"BF6500072_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 2000 343: 905\u2013914","journal-title":"N Engl J Med"},{"key":"BF6500072_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI915","volume":"101","author":"L Iyer","year":"1998","unstructured":"Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al . Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 1998 101: 847\u2013854","journal-title":"J Clin Invest"},{"key":"BF6500072_CR3","first-page":"3723","volume":"54","author":"E Gupta","year":"1994","unstructured":"Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ . Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 1994 54: 3723\u20133725","journal-title":"Cancer Res"},{"key":"BF6500072_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1542\/peds.10.4.397","volume":"10","author":"JF Crigler","year":"1952","unstructured":"Crigler JF, Najjar . Congenital familial nonhemolytic jaundice with kernicterus Pediatrics 1952 10: 169\u2013180","journal-title":"Pediatrics"},{"key":"BF6500072_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Boer A, Oostra BA . The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N Engl J Med 1995 333: 1171\u20131175","journal-title":"N Engl J Med"},{"key":"BF6500072_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","volume":"65","author":"L Iyer","year":"1999","unstructured":"Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al . Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 1999 65: 576\u2013582","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500072_CR7","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","volume":"95","author":"E Beutler","year":"1998","unstructured":"Beutler E, Gelbart T, Demina A . Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 95: 8170\u20138174","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BF6500072_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan G, Ryan M, Seddon R, Hume R, Burchell B . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 1996 347: 578\u2013581","journal-title":"Lancet"},{"key":"BF6500072_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00008571-199910000-00006","volume":"9","author":"D Hall","year":"1999","unstructured":"Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A . Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates Pharmacogenetics 1999 9: 591\u2013599","journal-title":"Pharmacogenetics"},{"key":"BF6500072_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1254\/fpj.105.447","volume":"105","author":"K Takasuna","year":"1995","unstructured":"Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M et al . Study on the mechanisms of diarrhea induced by the new anticancer drug irinotecan hydrochloride (CPT-11) Folia Pharmacol Jpn 1995 105: 447\u2013460","journal-title":"Folia Pharmacol Jpn"},{"key":"BF6500072_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1200\/JCO.1997.15.4.1502","volume":"15","author":"E Gupta","year":"1997","unstructured":"Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE et al . Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J Clin Oncol 1997 15: 1502\u20131510","journal-title":"J Clin Oncol"},{"key":"BF6500072_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1023\/A:1008261821434","volume":"8","author":"E Wasserman","year":"1997","unstructured":"Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M . Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports Ann Oncol 1997 8: 1049\u20131051","journal-title":"Ann Oncol"},{"key":"BF6500072_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1023\/A:1008438109725","volume":"9","author":"Y Ando","year":"1998","unstructured":"Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T . UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Annals Oncol 1998 9: 845\u2013847","journal-title":"Annals Oncol"},{"key":"BF6500072_CR14","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al . Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 2000 60: 6921\u20136926","journal-title":"Cancer Res"},{"key":"BF6500072_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJMoa010957","volume":"345","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL . Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer (letter) New Eng J Med 2001 345: 144\u2013145","journal-title":"New Eng J Med"},{"key":"BF6500072_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00008571-200008000-00007","volume":"10","author":"CS Huang","year":"2000","unstructured":"Huang CS, Luo GA, Huang ML, Yu SC, Yang SS . Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese Pharmacogenetics 2000 10: 539\u2013544","journal-title":"Pharmacogenetics"},{"key":"BF6500072_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s100380050100","volume":"44","author":"K Akaba","year":"19999","unstructured":"Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M et al . Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese J Hum Genet 1 999 44: 22\u201325","journal-title":"J Hum Genet 1"},{"key":"BF6500072_CR18","first-page":"21","volume":"46","author":"K Akaba","year":"1998","unstructured":"Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M et al . Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese Biochem Mol Biol Int 1998 46: 21\u201326","journal-title":"Biochem Mol Biol Int"},{"key":"BF6500072_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 2001 27: 383\u2013391","journal-title":"Nat Genet"},{"key":"BF6500072_CR20","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U\u2009S\u2009A 2000 97: 3473\u20133478","journal-title":"Proc Natl Acad Sci U\u2009S\u2009A"},{"key":"BF6500072_CR21","first-page":"196","volume":"32","author":"L Iyer","year":"2000","unstructured":"Iyer L, Ramirez J, Shepard DR, Hossfeld D-K, Ratain MJ, Mayer U . Role of p-glycoprotein (Pgp) in biliary excretion of irinotecan (CPT-11) in normal and mdr1a\/1b(\u2212\/\u2212) mice Drug Metab Rev 2000 32: 196 (Abst)","journal-title":"Drug Metab Rev"},{"key":"BF6500072_CR22","first-page":"2236","volume":"6","author":"HC Pitot","year":"2000","unstructured":"Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C et al . Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy Clin Cancer Res 2000 6: 2236\u20132244","journal-title":"Clin Cancer Res"},{"key":"BF6500072_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sim.4780040112","volume":"4","author":"J Cuzick","year":"1985","unstructured":"Cuzick J . A Wilcoxon-type test for trend Statistics in Medicine 1985 4: 87\u201390","journal-title":"Statistics in Medicine"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500072","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:19:20Z","timestamp":1647947960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1,1]]}},"alternative-id":["BF6500072"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500072","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,1]]},"assertion":[{"value":"4 September 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2001","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2001","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2002","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}